Skip to main content
OpenTrials
Completed

NCT Number: NCT02256969

Intraductal Meibomian Gland Probing Trial

In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms.

The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Meibomian Gland Dysfunction Eye Diseases Eyelid Diseases

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, 02114, United States

About this study

Dry eye disease is one of the most common conditions seen in ophthalmic practice and is associated with significant patient distress. Meibomian gland dysfunction (MGD) is among the most prevalent causes of dry eye disease. This condition, which is often due to obstruction of the meibomian gland orifices, may result in significant ocular irritation. Traditionally, management of MGD includes warm compress, lid hygiene, and anti-inflammatory medications. This randomized clinical trial is designed to evaluate the effects of meibomian gland probing versus sham procedure in cases with refractory MGD that do not respond to traditional treatments. Moreover, the effects of postoperative regimen will also be investigated using two different regimens. In addition to symptoms, the changes will also be evaluated in terms of clinical signs as well as in vivo confocal microscopy (IVCM) which allows study at the cellular level.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-89 years
  • Willing and able to provide written informed consent
  • Willing and able to comply with study assessments for the full duration of the study
  • Diagnosis of meibomian gland dysfunction (MGD)
  • Symptoms of MGD such as foreign body sensation, burning, stinging, light sensitivity for at least 3 months
  • Persistent symptoms despite at least 3 months of medical management including lid hygiene, warm compress, and use of topical and systemic therapy, or contraindication to systemic therapy
  • Presence of lid tenderness on the upper lids in both eyes
  • Tear break-up time (TBUT) of <10 seconds
  • In good stable overall health

Exclusion criteria

  • Active allergies to steroids, sulfacetamide, GenTeal PM Night-Time ointment, or lidocaine
  • Intraocular surgery or ocular laser surgery within 1 month before enrollment
  • History of ocular infection within 1 month before enrollment.
  • History of increased intraocular pressure after using topical steroids (steroid responsive)
  • Any condition (including language barrier) that precludes subject's ability to comply with study requirements including completion of study

Treatment and study plan

Blephamide

Drug

Other names: sulfacetamide sodium 10%/prednisolone acetate 0.2%, Allergan, Inc.

GenTeal PM Night-Time

Drug

Other names: GenTeal PM Night-Time Ophthalmic Ointment Alcon

Meibomian Gland Probing

Procedure

For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.

Sham Meibomian Gland Probing

Procedure

For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.

Primary outcomes

  1. Ocular Surface Disease Index (OSDI)

    Time frame: 4 week Time Point

    A 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms.

  2. Symptom Assessment in Dry Eye (SANDE)

    Time frame: 4 week Time Point

    A two-item survey used to assess the frequency and severity of dry eye disease. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

  3. Corneal Fluorescein Staining (CFS)

    Time frame: 4 week Time Point

    Is used to assess the level of corneal epitheliopathy that is related to dry eye disease. The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of epitheliopathy.

  4. Tear Break Up Time (TBUT)

    Time frame: 4 week Time Point

    TBUT measures the amount of time, in seconds, a dry spot appears in the tear film after each blink. Values less than 10 seconds are considered abnormal.

Sponsors and collaborators

Lead sponsor

Joseph B. Ciolino, MD

Other

Registry information

Official study title

Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction

Acronym: MGP

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Oct 6, 2014
Registry last updated
Jun 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.